Alla S Salasyuk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5559815/publications.pdf

Version: 2024-02-01

1162889 302012 2,714 63 8 citations h-index papers

39 g-index 68 68 68 2956 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	Blood pressure control, target organ protection and metabolic disorders control using a fixed combination of azilsartan medoxomil + chlorthalidone in hypertensive patients survived after severe and extremely severe COVID-19. Arterial Hypertension (Russian Federation), 2022, 27, 642-652.	0.1	O
2	Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part II. Russian Journal of Cardiology, 2022, 27, 4759.	0.4	3
3	Optimization of blood pressure control, organ protection and metabolic disorders using a fixed-dose combination of lisinopril+amlodipine+rosuvastatin in hypertensive patients after COVID-19. Russian Journal of Cardiology, 2022, 26, 4766.	0.4	2
4	Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts. Russian Journal of Cardiology, 2022, 26, 4791.	0.4	1
5	Pharmacoeconomic analysis of ferric carboxymaltose in patients with chronic heart failure and iron deficiency in the Russian Federation., 2022,, 30-43.		O
6	Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system. Sovremennaya Revmatologiya, 2021, 15, 119-127.	0.1	0
7	Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm. Farmakoekonomika, 2021, 13, 377-387.	0.4	3
8	INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES". Obesity and Metabolism, 2021, 18 , 5 -99.	0.4	49
9	Early vascular aging in patients with metabolic syndrome: features of the course and diagnosis. Ãמno-Rossijskij žurnal TerapevtiÄeskoj Praktiki, 2021, 2, 50-62.	0.1	1
10	Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I. Russian Journal of Cardiology, 2021, 26, 4368.	0.4	10
11	Resolution of an online meeting of the Siberian, Far Eastern and Southern Federal Districts experts on the results of the EMPEROR-Reduced trial "Therapeutic approaches in heart failure with reduced ejection fraction: the EMPA-REG OUTCOME trial and the EMPEROR-Reduced trial― Complex Issues of Cardiovascular Diseases, 2021, 10, 121-129.	0.3	O
12	Identifying Early Vascular Ageing in Patients With Metabolic Syndrome: Unresolved Issues and a Proposed Novel VAmets Score. Heart Lung and Circulation, 2021, 30, 1752-1761.	0.2	4
13	Budget impact analysis of ertugliflozin in patients with type 2 diabetes mellitus who failed to achieve glycemic targets on metformin. Ã^ndokrinologiâ Novosti, Mneniâ, ObuÄenie, 2021, 10, 33-43.	0.0	O
14	Pharmacoeconomic analysis of acalabrutinib in patients with chronic lymphocytic leukemia. Journal of Modern Oncology, 2021, 23, 612-620.	0.1	1
15	Clinical and economic analysis of using dapagliflozin in patients with chronic kidney disease in the Russian Federation. Consilium Medicum, 2021, 23, 932-938.	0.1	0
16	The effect of various classes of glucose-lowering medications on the blood vessel elasticity in patients with type 2 diabetes. Russian Journal of Cardiology, 2020, 25, 3766.	0.4	3
17	Azilsartan medoxomil for improving insulin resistance and adipokine levels in hypertension in comparison with angiotensin-converting enzyme inhibitors. Russian Journal of Cardiology, 2020, 25, 3767.	0.4	1
18	Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration. Rossiiskii Oftal'mologicheskii Zhurnal, 2020, 13, 42-50.	0.1	2

#	Article	IF	CITATIONS
19	Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation. Farmakoekonomika, 2020, 13, 101-111.	0.4	0
20	Optimal Organ Protection and Blood Pressure Control with the Single Pill Combination Lisinopril, Amlodipine and Indapamide in Arterial Hypertension. Rational Pharmacotherapy in Cardiology, 2020, 16, 931-937.	0.3	1
21	Pharmacoeconomic analysis of the use of dapagliflozin in patients with NYHA class II–IV chronic heart failure with reduced left ventricular ejection fraction â‰ 4 0% in the Russian Federation. Consilium Medicum, 2020, 22, 45-51.	0.1	4
22	Clinical and economic aspects of bulevirtide use in patients with chronic hepatitis D. Infektsionnye Bolezni, 2020, 18, 104-111.	0.2	1
23	Early vascular aging risk assessment in patients with metabolic syndrome. European Heart Journal, 2020, 41, .	1.0	O
24	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, The, 2019, 394, 121-130.	6.3	1,625
25	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, The, 2019, 394, 131-138.	6.3	394
26	PRS4 HEALTH TECHNOLOGY ASSESSMENT OF DUPILUMAB IN SEVERE BRONCHIAL ASTHMA IN THE RUSSIAN FEDERATION. Value in Health Regional Issues, 2019, 19, S77.	0.5	0
27	Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs. Russian Journal of Cardiology, 2019, , 70-79.	0.4	10
28	Pharmacoeconomic rationale for alirocumab administration in acute coronary syndrome. Military Thought, 2019, 28, 99-104.	0.1	1
29	Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria. Farmakoekonomika, 2019, 12, 72-84.	0.4	2
30	Pharmacoeconomic analysis of the anidulafungin (EraxisR) in adult patients with invasive candidiasis. Oncogematologiya, 2019, 14, 98-108.	0.1	0
31	PRM101 - THE COST BURDEN OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN RUSSIAN FEDERATION. Value in Health, 2018, 21, S373.	0.1	0
32	OPTIMALÂORGANOPROTECTION,ÂCONTROLÂOFÂbLOODÂPRESSUREÂANDÂMETAbOLICÂDISORDERÂ WITHÂTHEÂFIxEDÂCOMbINATIONÂOFÂLISINOPRIL,ÂAMLODIPINEÂANDÂROSUVASTATINÂINÂSYSTEMICÂ HYPERT Russian Journal of Cardiology, 2018, , 49-55.	ENSION.	7
33	ADDITIONALÂANGIOPROTECTIONÂANDÂMETAЬOLICÂDISORDERSÂCORRECTIONÂINÂTREATMENTÂÂ OFÂARTERIALÂHYPERTENSIONÂPATIENTSÂREACHEDÂTARGETÂЬLOODÂPRESSUREÂLEVELS,ÂÂ WITHÂFIxEDÂCOMЫNATIONÂOFÂPERINDOPRILÂANDÂINDAPAMIDE. Russian Journal of Cardiology, 2018, , 67-74	0.4	1
34	Metabolic syndrome and kidney: nephroprotection and reduction of cardiovascular risk. Arterial Hypertension (Russian Federation), 2018, 24, 369-378.	0.1	2
35	Optimization of Blood Pressure Control, Metabolic Parameters, and Target Organs Protection with Perindopril + Indapamide Fixed Combination in Hypertensive Patients with Obesity and Prediabetes. Diabetes, 2018, 67, 129-LB.	0.3	1
36	Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin. Systemic Hypertension, 2018, 15, 24-31.	0.1	3

3

#	Article	IF	Citations
37	The economic burden of chronic thromboembolic pulmonary hypertension in Russian Federation. Terapevticheskii Arkhiv, 2018, 90, 101-109.	0.2	16
38	The Influence of Empagliflozin on Vascular Age and Key Cardiovascular Risk Factors in Type 2 Diabetes Mellitus Patients. Doctor Ru, 2018, 152, 6-11.	0.1	0
39	Pharmacoeconomic Analysis of Tiotropium Bromide and Olodaterol Fixed Combination as Maintenance Therapy in Patients with Chronic Obstructive Pulmonary Disease in Russian Federation. Medical Technologies Assessment and Choice (ĐœĐμĐĐ¸Ñ†Đ¸Đ½ÑаиĐμ Ñ,ĐμÑĐ½Đ¾Đ»Đ¾Đ³Đ,и ĐžÑ†ĐμĐ½Đ°Đ	O.1 ° Đ¸Đ²Ñ‹Đ	0 0±Đ¾Ñ€), 2
40	Blood pressure control and vascular protection with a fixed-dose combination of lisinopril + amlodipine + rosuvastatin in hypertensive patients. Vessel Plus, 2018, 2, 37.	0.4	1
41	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 723-732.	13.9	480
42	CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology, 2017, 13, 45-50.	0.3	2
43	EFFECTS OF MELATONIN ON BLOOD PRESSURE, ENDOTHELIAL FUNCTION AND VASCULAR STIFFNESS IN PATIENTS WITH METABOLIC SYNDROME AND SLEEP DISORDERS. Arterial Hypertension (Russian) Tj ETQq1 1 0.78	4 3.1 4 rgB7	Γ¢Overloc <mark>k</mark>
44	NATIONAL CLINICAL RECOMMENDATIONS FOR OBESITY: CONCEPT AND PROSPECTS. , 2017, 61, 134-140.		12
45	Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis. Sovremennaya Revmatologiya, 2017, 11, 88-95.	0.1	O
46	SLOW RELEASE MELATONINE IN METABOLIC SYNDROME SYMPTHOMATICS CORRECTION. Russian Journal of Cardiology, $2016, , 61-67.$	0.4	2
47	WAYS OF MENOPAUSAL HORMONAL THERAPY IN CORRECTION OF METABOLIC DISORDERS AND ANGIOPROTECTION IN POSTMENOPAUSAL WOMEN. Russian Journal of Cardiology, 2016, , 70-75.	0.4	O
48	COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN. Farmakoekonomika, 2016, 9, 58-68.	0.4	0
49	The possibility of perindopril in angioprotective in patients with metabolic syndrome after combination therapy with a thiazide diuretic. Systemic Hypertension, 2016, 13, 30-33.	0.1	O
50	Possibilities of indapamide for angioprotection in patients with metabolic syndrome following treatment with thiazide-containing combinations. Russian Heart Journal, 2016, 15, 192-196.	0.1	1
51	Prevalence of metabolic syndrome and testosterone replacement therapy in mans with andropause. Maturitas, 2015, 81, 212.	1.0	O
52	The quality of life for women in a period of menopause. Maturitas, 2015, 81, 178.	1.0	0
53	Effects of Testosterone Replacement Therapy on Cardio-Metabolic, Hormonal and Anthropometric Parameters in Obese Hypogonadal Men with Metabolic Syndrome. Obesity, Open Access, 2015, 1, .	0.1	1
54	The influence of fixed-dose combination of amlodipine and bisoprolol on vascular elasticity in patients with arterial hypertension. Consilium Medicum, 2015, 17, 19-22.	0.1	1

#	Article	IF	CITATIONS
55	Losartan versus Telmisartan in Overweight Patients with Arterial Hypertension. Journal of Advanced Clinical Pharmacology, 2015, 2, 1-7.	0.5	1
56	Randomized Trial of Perindopril, Enalapril, Losartan and Telmisartan in Overweight or Obese Patients with Hypertension. Clinical Drug Investigation, 2013, 33, 553-561.	1.1	52
57	COMPARATIVE EFFECTIVENESS OF FIXED-DOSE COMBINATIONS OF LISINOPRIL/AMLODIPINE AND ENALAPRIL/HYDROCHLOROTHIAZIDE. Cardiovascular Therapy and Prevention (Russian Federation), 2013, 12, 25-29.	0.4	2
58	Effect of angiotensin II receptor antagonists on left ventricular hypertrophy, vascular elasticity, and lipid and carbohydrate metabolic parameters in metabolic syndrome. Systemic Hypertension, 2013, 10, 27-33.	0.1	1
59	Comparative analysis of the efficiency of the selective b-blocker nebivolol and the angiotensin II receptor blocker valsartan in men with hypertension, metabolic syndrome, and erectile dysfunction. Cardiosomatics, 2013, 4, 57-66.	0.2	O
60	Self-management of diabetes. Cardiosomatics, 2013, 4, 17-20.	0.2	0
61	Sravnitel'naya effektivnost' perindoprila A i telmisartana u patsientov s arterial'noy gipertenziey i ozhireniem. Systemic Hypertension, 2012, 9, 33-39.	0.1	O
62	The abilities of losartan in angioprotection in hypertensive patients with hyperuricemia. Systemic Hypertension, 2012, 9, 16-21.	0.1	0
63	Improving the efficacy of antihypertensive therapy with the use of fixed-dose combination therapy. Arterial Hypertension (Russian Federation), 2011, 17, 513-517.	0.1	O